The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

BD invested $10 million last year to increase manufacturing capacity. The recent expansion has created more than 200 jobs.

Retractable Technologies, Inc. (NYSA: RVP) recently made headlines by withdrawing its complaint in the United States Court of International Trade on January 8, 2025. The company issued a press release ...

Mayor Mike Johnston had only vetoed one bill during his time in office until Tuesday, when he said an ordinance removing certain restrictions for needle exchange sites was the "wrong solution." ...

BD (NYSE: BDX) announced today that it plans to invest further in U.S. manufacturing to add capacity for certain critical ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

City councilwoman Amanda Sawyer, who opposed the bill, said a needle exchange in her district has been a ‘terrible neighbor.’ ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

FlowBeams, creator of the BoldJet needle-free injection showcased itsbreakthrough medtech technology at CES 2025.The ...

Smart syringes redefine modern injection protocols through built-in safety features and automated monitoring. Heightened ...

The shock syringe is designed to deliver the medication rapidly. However, if a regular syringe is inserted too quickly or ...